Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 18, 2023
Distillery Therapeutics

Keratin-derived peptides for corneal inflammation and infection

BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

An overview of how therapies in clinical trials for coronavirus interfere with viral biology
BioCentury | Jul 24, 2019
Distillery Therapeutics

Simultaneous CLEC5A and TLR2 inhibition for dengue

BioCentury | Oct 11, 2018
Distillery Therapeutics

Infectious disease

BioCentury | Jul 24, 2018
Distillery Therapeutics

Neurology; autoimmune disease

BioCentury | Mar 9, 2018
Clinical News

VBL's VB-111 misses in Phase III for glioblastoma

BioCentury | Mar 8, 2018
Clinical News

VBL falls on Phase III glioblastoma miss

Items per page:
1 - 10 of 73